 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper129th MAINE LEGISLATURE
FIRST REGULAR SESSION-2019
Legislative Document No. 1272
S.P. 392 In Senate,  March  14, 2019
An Act  To Increase Access to Low-cost  Prescription Drugs
Reference to the Committee on Health  Coverage, Insurance and Financial Services 
suggested and ordered printed.
DAREK M.  GRANT
Secretary of the Senate
Presented by President JACKSON of Aroostook.
Cosponsored by Speaker  GIDEON of Freeport and
Senators: CLAXTON of Androscoggin, MOORE of Washington, VITELLI of Sagadahoc, Representatives: FECTEAU of  Biddeford,  FOLEY of Biddeford, MASTRACCIO of Sanford, 
PERRY of  Calais, TEPLER of Topsham.

Page 1 - 129LR0972(01)-11Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  5 MRSA c. 167 is enacted to read:
3CHAPTER 167
4WHOLESALE PRESCRIPTION DRUG IMPORTATION PROGRAM 
5ยง2041.  Authorization
6The Wholesale Prescription Drug Importation Program, referred to in this chapter as 
7"the program," is established to provide for the wholesale importation of prescription 
8drugs from Canada by or on behalf of the State.  The program must be designed in 
9accordance with the requirements of this chapter.  The program may not be implemented 
10unless the State obtains approval and certification, pursuant to section 2042, subsection 3, 
11from the United States Department of Health and Human Services.
12ยง2042.  Design of program
131.  Design requirements.  The Department of Health and Human Services, in 
14consultation with appropriate federal and other state agencies and interested parties, shall 
15design the program to comply with the applicable requirements of 21 United States Code, 
16Section 384, including requirements regarding safety and cost savings.  The program 
17design must:
18A.  Designate a state agency to become a licensed drug wholesaler or to contract with 
19a licensed drug wholesaler in order to seek federal certification and approval, 
20pursuant to section 2042, subsection 3, to import safe prescription drugs and provide 
21cost savings to consumers in the State;
22B.  Use prescription drug suppliers in Canada regulated under the laws of Canada or 
23of one or more Canadian provinces, or both;
24C.  Ensure that only prescription drugs meeting the federal Food and Drug 
25Administration's safety, effectiveness and other standards are imported by or on 
26behalf of the State;
27D.  Import only those prescription drugs expected to generate substantial cost savings 
28for consumers in the State;
29E.  Ensure that the program complies with the transaction and tracing requirements of 
3021 United States Code, Sections 360eee and 360eee-1 to the extent feasible and 
31practical prior to imported prescription drugs coming into the possession of the 
32licensed drug wholesaler and that the program complies fully with those federal 
33requirements after imported prescription drugs are in the possession of the licensed 
34drug wholesaler;
35F.  Prohibit the distribution, dispensing or sale of imported prescription drugs outside 
36of the State;
Page 2 - 129LR0972(01)-11G.  Recommend a charge per prescription or another method of financing to ensure 
2that the program is adequately funded in a manner that does not jeopardize significant 
3cost savings to consumers; and
4H.  Include an audit function.
52.  Rules.  The Department of Health and Human Services shall adopt rules to design 
6the program in accordance with the requirements of subsection 1 no later than January 1, 
72020. Rules adopted pursuant to this subsection are major substantive rules as defined in 
8chapter 375, subchapter 2-A.
93.  Request for federal approval and certification.  The Department of Health and 
10Human Services shall submit a request for approval and certification of the program to 
11the United States Department of Health and Human Services no later than May 1, 2020.
12ยง2043.  Implementation
131.  Implementation; operation.  Upon receipt of federal approval and certification 
14under section 2042, subsection 3, the state agency designated to oversee the program 
15pursuant to this chapter shall implement the program as required in subsection 2.  The 
16program must begin operating no later than 6 months following receipt of federal 
17approval and certification.
182.  Requirements.  Prior to operating the program, the state agency designated to 
19oversee the program pursuant to this chapter shall:
20A.  Become a licensed drug wholesaler or enter into a contract with a licensed drug 
21wholesaler in the State;
22B.  Contract with one or more distributors licensed in the State;
23C.  Contract with one or more licensed and regulated prescription drug suppliers in 
24Canada;
25D.  Consult with health insurance carriers, employers, pharmacies, pharmacists, 
26health care providers and consumers;
27E.  Develop a registration process for health insurance carriers, pharmacies and health 
28care providers authorized to prescribe and administer prescription drugs that are 
29willing to participate in the program;
30F.  Create a publicly accessible website for listing the prices of prescription drugs to 
31be imported under the program;
32G.  Create an outreach and marketing plan to generate public awareness of the 
33program;
34H.  Provide a telephone hotline to answer questions and address needs of consumers, 
35employers, health insurance carriers, pharmacies, health care providers and others 
36affected by the program;
37I.  Develop a 2-year audit work plan; and
Page 3 - 129LR0972(01)-11J.  Conduct any other activity determined necessary to successfully implement and 
2operate the program.
3ยง2044.  Annual reporting
4Beginning January 2021, and annually thereafter, the Department of Health and 
5Human Services, or other state agency designated to oversee the program pursuant to this 
6chapter, shall report to the joint standing committee of the Legislature having jurisdiction 
7over health coverage and prescription drugs regarding the implementation and operation 
8of the program during the previous calendar year, including:
91.  Prescription drugs included.  The prescription drugs included in the program;
102.  Participation.  The number of participating pharmacies, health care providers and 
11health insurance carriers;
123.  Prescriptions dispensed.  The number of prescription drugs dispensed through 
13the program;
144.  Estimated savings.  The estimated cost savings to consumers, health insurance 
15carriers, employers and the State during the previous calendar year and to date;
165.  Audit findings.  Information regarding implementation of the audit work plan and 
17audit findings; and
186.  Other relevant information.  Any other information the Department of Health 
19and Human Services, or other state agency designated to oversee the program pursuant to 
20this chapter, considers relevant.
21SUMMARY
22This bill establishes a wholesale importation program for prescription drugs from 
23Canada by or on behalf of the State in order to provide cost savings to consumers.  The 
24bill requires the Department of Health and Human Services to design the program 
25through rulemaking by January 1, 2020.  The rules are designated as major substantive 
26and must be submitted to the Legislature for final approval.  The bill also specifies that 
27the program may not be implemented until the State has received federal approval and 
28certification.  The bill directs the Department of Health and Human Services to apply for 
29federal approval no later than May 1, 2020. 
